A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : LAPC / locally advanced pancreatic cancer

[Related PubMed/MEDLINE]
Total Number of Papers: 320
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   LAPC  (>> Co-occurring Abbreviation)
Long Form:   locally advanced pancreatic cancer
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. ---
2020 Clinical application of dynamic contrast enhanced ultrasound in monitoring the treatment response of chemoradiotherapy of pancreatic ductal adenocarcinoma. CRT, DCE-US, MI, MTT, ROIs, RT, TICs, TTP
2020 Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer. GemCap, OS, PFS
2020 Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer. CSS, IRE, OS, PFS, PSM, SEER, SYSUCC
2020 Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1). CHT, DMFS, LC, OS, SBRT
2020 Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score matching analysis. IRE, OS, PFS, PSM
2020 Is there a Role for the Appleby Procedure in 2020? Results from a Matched-Pair-Analysis. PPH, SDP
2020 Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia. IRE, OS, PFS
2020 Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy. OS, PFS, SBRT
10  2020 Proton and carbon ion radiation therapy for locally advanced pancreatic cancer: A phase I dose escalation study. DLT, GI, MTD, PCRT
11  2020 The role of cystoprostatectomy in management of locally advanced prostate cancer: a systematic review. ---
12  2020 The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer. OS, OS, SR
13  2020 Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial. Ad5-DS, DLT, vp
14  2019 A case of pancreatic cancer invading the superior mesenteric artery causing extensive intestinal necrosis that was successfully treated by surgery. SMA
15  2019 A model-based patient selection tool to identify who may be at risk of exceeding dose tolerances during pancreatic SBRT. OAR
16  2019 A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. MSI, PARPi, RT, TMB
17  2019 A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. IRE, KM, OS, PFS, TTP
18  2019 Ablation treatments in unresectable pancreatic cancer. ---
19  2019 Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study. IOUS
20  2019 Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. LAPC-N, LAPC-N-S, LAPC-S, mFOLFIRINOX, OS, PFS, RPC
21  2019 Cachectic Body Composition and Inflammatory Markers Portend a Poor Prognosis in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation. CRP, CRT, SCF, SM, VF
22  2019 CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial. ---
23  2019 Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. ---
24  2019 Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer. OAR, PTV
25  2019 Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. CCRT, GyE, LC, MST, OS
26  2019 Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer. cCRT, ICT, OS
27  2019 Conversion Surgery for Advanced Pancreatic Cancer. NAT
28  2019 Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. CT, NAT, PET
29  2019 Early variation of 18-fluorine-labelled fluorodeoxyglucose PET-derived parameters after chemoradiotherapy as predictors of survival in locally advanced pancreatic carcinoma patients. CRT, DeltaGICA, DRFS, LRFS, OS, PFS
30  2019 Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. CWL, OS, PS, WL
31  2019 Effect of Tumor Burden on Tumor Aggressiveness and Immune Modulation in Prostate Cancer: Association with IL-6 Signaling. CSC, EMT
32  2019 Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). OS, PFS, SBRT
33  2019 Elderly patients aged ≥ 75years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis. CSM, LT, MVA CRR, NLT, OCM, PSM, RP, RT, SHR
34  2019 Evaluation of a simplified optimizer for MR-guided adaptive RT in case of pancreatic cancer. GTV, IMRT, MRgART, OARs, TPS, VMAT
35  2019 Exocrine pancreatic and enterocyte function in patients with advanced pancreatic cancer. CGT, Cit, Glu, IRE
36  2019 Identification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiation therapy. MRgRT, OAR
37  2019 Immunomodulatory Effect after Irreversible Electroporation in Patients with Locally Advanced Pancreatic Cancer. C-index, IRE, OS, PFS, ROC
38  2019 Intraoperative Irreversible Electroporation in Locally Advanced Pancreatic Cancer: A Guide for the Interventional Radiologist. IRE
39  2019 Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. IRE, Treg, WT
40  2019 Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis. IRE, OS, PFS, PSM
41  2019 Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. CT, gem-nab
42  2019 Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma. ---
43  2019 Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice. ---
44  2019 Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. BRPC, CIs
45  2019 Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. NG, ORR
46  2019 Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination? IRE, MWA, PDAC, RFA
47  2019 Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. DFS, FFN, GemNab, mOS, OS
48  2019 Novel implications of combined arterial resection for locally advanced pancreatic cancer in the era of newer chemo-regimens. AR, OS, RFS
49  2019 Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. ---
50  2019 Pancreaticoduodenectomy with Mesocaval Shunt for Locally Advanced Pancreatic Adenocarcinoma. IVC, LIJ, PD, SMV
51  2019 PANOVA-3: A phase 3 study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC). ---
52  2019 Percutaneous Irreversible Electroporation as First-line Treatment of Locally Advanced Pancreatic Cancer. IRE
53  2019 Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer. OS, PDT, PFS
54  2019 Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy. ALI, CCRT, PFS, ROC
55  2019 Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy. CRT, HR, LDT, MTV, OS, PFS, SBRT, TLG
56  2019 Quality of life among patients after cystoprostatectomy as the treatment for locally advanced prostate cancer with bladder invasion. FACT-P, QOL
57  2019 Quality of life assessment for patients undergoing irreversible electroporation (IRE) for treatment of locally advanced pancreatic cancer (LAPC). IRE, QOL
58  2019 Safety, Efficacy, and Technical Details of Endoscopic Retrograde Cholangiopancreatography After Irreversible Electroporation for Locally Advanced Pancreatic Cancer. ERCP, IRE
59  2019 Stereotactic body radiation therapy for locally advanced pancreatic cancer. CT, FFLP, OS, PFS, SBRT
60  2019 Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). GEMABX
61  2019 Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience. BRPC, NAT
62  2019 Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. OS, PMDC
63  2019 Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer. IRE
64  2019 Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. IRE
65  2019 The role of biological dose-escalation for pancreatic cancer. SBRT, SMART
66  2019 The Utility of EUS-FNA to Determine Surgical Candidacy in Patients with Pancreatic Cancer after Neoadjuvant Therapy. BRPC, PSTC
67  2019 Treatment of locally advanced pancreatic cancer with irreversible electroporation - a Danish single center study of safety and feasibility. IRE, LOS, OS, VAS
68  2019 Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers. ACs, HR, HVFs, MAC, MVA, OS, RT
69  2019 Venous Resection for Locally Advanced Pancreatic Cancer: Time Trend and Outcome Analysis of 65 Consecutive Resections at a High-Volume Center. ---
70  2019 Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases. ---
71  2019 [New progress in the treatment of locally advance pancreatic cancer]. ---
72  2018 A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy. CRT, FDG-PET, OS
73  2018 A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer. C-ion RT, CI, GI, LC, OS, PFS, RBE
74  2018 Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. NPV, PPV
75  2018 Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. CRT, DMFS, FX, LC, OS, RECIST
76  2018 Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. AJCC, CRT, CT, NCDB, OS, PSM, RT, SBRT
77  2018 Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. BRPC, pCR
78  2018 Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. DMS, GI, IMRT, LRPFS, OS
79  2018 Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience. cRDI, OS
80  2018 Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac. CCRT, DMFS, DTT-IMRT, GI, LRPFS, OS
81  2018 Combination of Pre-Treatment DWI-Signal Intensity and S-1 Treatment: A Predictor of Survival in Patients with Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy and Sequential S-1. DWI, IBS, OS, PEC, ROI
82  2018 Combined Inter- and Intrafractional Plan Adaptation Using Fraction Partitioning in Magnetic Resonance-guided Radiotherapy Delivery. GTV, MRgRT, OARs, PTVOPT
83  2018 Computed tomography findings after radiofrequency ablation in locally advanced pancreatic cancer. CT, RFA
84  2018 Conversion surgery for an initially unresectable, locally advanced pancreatic cancer after induction chemotherapy and carbon-ion radiotherapy: a case report. CIRT, SSPPD
85  2018 Current and emerging radiotherapy strategies for pancreatic adenocarcinoma: stereotactic, intensity modulated and particle radiotherapy. IMRT, SBRT
86  2018 Effect of Neoadjuvant Hormone Therapy on Resection Margin and Survival Prognoses in Locally Advanced Prostate Cancer after Prostatectomy Using Propensity-Score Matching. BCR, NHT, OS
87  2018 Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction chemotherapy for locally advanced pancreatic cancer. CRT, LPFS, OS, PFS, SIB-IMRT
88  2018 Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer: A meta-analysis of randomized controlled trials. CRT, CT, ORs, RCTs
89  2018 Evaluation of Dynamic Tumor-tracking Intensity-modulated Radiotherapy for Locally Advanced Pancreatic Cancer. DTT-IMRT, IMRT
90  2018 Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy. BMI, BRPC, BSA, CT, GI, ROC, SBRT, TPA
91  2018 Irreversible electroporation for locally advanced pancreatic cancer through a minimally invasive surgery supported by laparoscopic ultrasound. IRE
92  2018 Irreversible Electroporation for Nonthermal Tumor Ablation in Patients with Locally Advanced Pancreatic Cancer: Initial Clinical Experience in Japan. IRE, OS
93  2018 Irreversible Electroporation in pancreatic ductal adenocarcinoma: Isthere a role in conjunction with conventional treatment? IRE, PDAC
94  2018 Large database utilization in health outcomes research in pancreatic cancer: an update. NCDB, SBRT, SEER, US
95  2018 Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery. BED, CBCT, FFF, OARs, SBRT, VMAT
96  2018 Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. ---
97  2018 Locally advanced prostate cancer. Definition, diagnosis and treatment. mpMRI
98  2018 Management of unresectable, locally advanced pancreatic adenocarcinoma. CRT, GEM, OS, RT
99  2018 Measurement of copy number of ACTN4 to optimize the therapeutic strategy for locally advanced pancreatic cancer. ACTN4, CRT
100  2018 Microwave ablation of pancreatic tumors. MWA